These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30191087)

  • 21. Tardive Dyskinesia: New Treatments Available.
    Limandri BJ
    J Psychosoc Nurs Ment Health Serv; 2019 May; 57(5):11-14. PubMed ID: 31042295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical management of tardive dyskinesia: Five steps to success.
    Citrome L
    J Neurol Sci; 2017 Dec; 383():199-204. PubMed ID: 29246613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis.
    Mentzel TQ; van der Snoek R; Lieverse R; Oorschot M; Viechtbauer W; Bloemen O; van Harten PN
    J Clin Psychiatry; 2018 Sep; 79(6):. PubMed ID: 30257080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.
    Bordia T; Zhang D; Perez XA; Quik M
    Exp Neurol; 2016 Dec; 286():32-39. PubMed ID: 27658674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antipsychotic-induced tardive syndromes].
    Fleischhacker WW; Hofer A; Jagsch C; Pirker W; Psota G; Rittmannsberger H; Seppi K
    Neuropsychiatr; 2016 Sep; 30(3):123-130. PubMed ID: 27580887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of tardive dyskinesia: use of dopamine-depleting agents.
    Fahn S
    Clin Neuropharmacol; 1983 Jun; 6(2):151-8. PubMed ID: 6133619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological treatment of tardive dyskinesia: recent developments.
    Caroff SN; Campbell EC; Carroll B
    Expert Rev Neurother; 2017 Sep; 17(9):871-881. PubMed ID: 28727483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia.
    Lu JY; Tiwari AK; Zai GC; Rastogi A; Shaikh SA; Müller DJ; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Wong AHC; Kennedy JL; Zai CC
    Neurosci Lett; 2018 Nov; 686():17-22. PubMed ID: 30118782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of dopamine antagonists in spontaneous and tardive dyskinesia.
    Fog R
    Psychopharmacology Suppl; 1985; 2():118-21. PubMed ID: 2860655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tardive Dyskinesia: Treatment Update.
    Arya D; Khan T; Margolius AJ; Fernandez HH
    Curr Neurol Neurosci Rep; 2019 Aug; 19(9):69. PubMed ID: 31420757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
    Claassen DO; Philbin M; Carroll B
    Expert Opin Pharmacother; 2019 Dec; 20(18):2209-2221. PubMed ID: 31613641
    [No Abstract]   [Full Text] [Related]  

  • 32. Historical perspectives on tardive dyskinesia.
    Caroff SN; Ungvari GS; Cunningham Owens DG
    J Neurol Sci; 2018 Jun; 389():4-9. PubMed ID: 29454494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia.
    Malik P; Andersen MB; Peacock L
    Pharmacol Biochem Behav; 2004 Aug; 78(4):805-10. PubMed ID: 15301939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia.
    Meyer JM
    CNS Spectr; 2016 Dec; 21(S1):13-24. PubMed ID: 28044943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
    Tsai G; Goff DC; Chang RW; Flood J; Baer L; Coyle JT
    Am J Psychiatry; 1998 Sep; 155(9):1207-13. PubMed ID: 9734544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tardive dyskinesia: pathophysiology and animal models.
    Casey DE
    J Clin Psychiatry; 2000; 61 Suppl 4():5-9. PubMed ID: 10739324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sulpiride in tardive dyskinesia.
    Gerlach J; Casey DE
    Acta Psychiatr Scand Suppl; 1984; 311():93-102. PubMed ID: 6142590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Electrophysiological and pharmacological analysis of L-dopa-induced dyskinesia and tardive dyskinesia (author's transl)].
    Bathien N; Rondot P; Koutlidis RM
    J Physiol (Paris); 1981 Apr; 77(1):131-41. PubMed ID: 6112268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia.
    Vijayakumar D; Jankovic J
    Drugs; 2016 May; 76(7):779-87. PubMed ID: 27091214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.